This is a register-based cross-sectional study analyzing 2,200 medical visits across 11 primary healthcare facilities (5 public and 6 private) in Abomey-Calavi, South Benin. It examined associations between metronidazole (MTZ) prescription and clinical presentations, with MTZ as the second most commonly prescribed antibiotic in the area. The study did not involve an intervention or comparator in a trial sense, but compared MTZ prescriptions to non-MTZ prescriptions based on recorded symptoms.
Key findings from adjusted analyses show MTZ prescription was associated with increased odds for digestive symptoms (aOR, 8.65; 95% CI, 6.49-11.6), genitourinary symptoms (aOR, 6.84; 95% CI, 3.18-15.0), and skin lesions (aOR, 2.39; 95% CI, 1.58-3.60). Conversely, it was associated with decreased odds for fever (aOR, 0.66; 95% CI, 0.49-0.87), respiratory symptoms (aOR, 0.44; 95% CI, 0.26-0.71), and malaria (aOR, 0.21; 95% CI, 0.15-0.28). Prescribing was also higher in the private sector compared to public (aOR, 2.31; 95% CI, 1.78-3.02). Safety data, such as adverse events, were not reported.
The authors acknowledge limitations, including the need for further studies to assess prescription appropriateness and to understand determinants of higher antimicrobial prescribing in the private sector. As an observational study, it shows associations rather than causation, and follow-up duration was not reported. Practice relevance is restrained: MTZ use in this setting appears driven largely by digestive symptoms, but findings should be interpreted cautiously due to the cross-sectional design and lack of clinical outcome data.
View Original Abstract ↓
Background: Metronidazole (MTZ) is a first-line antibiotic for several enteric infections. Its use is common in low-income countries, where most primary-care consultations are conducted by nurses. However, increasing resistance among some enteric pathogens is a growing concern. Using WHO guidelines, we conducted a register-based cross-sectional study to assess MTZ prescribing practices and their determinants in public and private primary healthcare facilities in South Benin. Methods: We performed a register-based cross-sectional study covering the year 2020 in 11 primary healthcare facilities (5 public and 6 private) in Abomey-Calavi, South Benin, following WHO recommendations. In total, 200 visits per facility were selected using systematic random sampling. The primary outcome was the prevalence of MTZ prescription. Determinants of MTZ prescription were identified using multivariable logistic regression analysis. Results: In total, 2,200 medical visits were analyzed. The median age of patients was 19 years, and 57% were female. Antimalarials were prescribed in 52% of visits. Antibacterial agents were prescribed in the majority of visits, with MTZ being the second most frequently prescribed antibiotic (18%), after aminopenicillins (27%). In multivariable analysis, digestive symptoms (adjusted odds ratio [aOR], 8.65; 95% confidence interval [CI], 6.49-11.6), genitourinary symptoms (aOR, 6.84; 95% CI, 3.18-15.0), and skin lesions (aOR, 2.39; 95% CI, 1.58-3.60) were independently associated with increased odds of MTZ prescription. In contrast, fever (aOR, 0.66; 95% CI, 0.49-0.87), respiratory symptoms (aOR, 0.44; 95% CI, 0.26-0.71), and malaria (aOR, 0.21; 95% CI, 0.15-0.28) were associated with decreased odds. Visits in the private sector were also associated with higher odds of MTZ prescription compared with the public sector (aOR, 2.31; 95% CI, 1.78-3.02). Conclusion: MTZ is the second most commonly prescribed antibiotic in primary care in the study area, with its use largely driven by digestive symptoms. Further studies are needed to assess the appropriateness of this prescription. Additionally, research is warranted to understand better the determinants of higher antimicrobial prescribing in the private healthcare sector.